Neoadjuvant Immunotherapy for dMMR and pMMR Colorectal Cancers: Therapeutic Strategies and Putative Biomarkers of Response

The authors describe the current and emerging clinical evidence supporting the use of neoadjuvant immune-checkpoint inhibitors in patients with DNA mismatch repair deficiency and proficient DNA mismatch repair colorectal cancer, and the potential advantages of such an approach.